BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2010

View Archived Issues

Trophos claims new cytoprotective agents

Read More

Scynexis discloses new antiviral cyclosporin A derivatives

Read More

NeuroSearch discovers new anticonvulsant agents

Read More

Cannabidiol displays antiangiogenic activity in preclinical tests

Read More

RGS1, IL12A and MPHOSPH9/CDK2AP1 gene SNPs are linked to susceptibility to MS

Read More

CONDOR data disclosed on GI safety of celecoxib vs. diclofenac/omeprazole in arthritis

Read More

Aragon doses first patient in phase I/II ARN-509 trial in prostate cancer

Read More

Vectura and GSK sign license agreement for dry powder drug formulations

Read More

Pluristem presents preclinical in vivo data on PLX cell therapy for pain

Read More

FDA seeks injunction against Regenerative Sciences for cultured cell product

Read More

Celgene's pomalidomide receives E.U. orphan drug status for myelofibrosis

Read More

Nabilone shows promise to treat cannabis use disorders

Read More

Curis provides update on phase II vismodegib trial in advanced ovarian cancer

Read More

Obeticholic acid receives E.U. orphan drug status for primary biliary cirrhosis

Read More

SNS-032 shows moderate activity in phase I trial in B-cell malignancies

Read More

European researchers describe new Aurora kinase A inhibitors

Read More

EMA grants octenidine orphan drug status for sepsis in premature infants

Read More

Daiichi Sankyo presents new agents for treatment of osteoporosis

Read More

HBGF-1-coated biodegradable device receives E.U. orphan drug status for spinal cord injury

Read More

Repros receives positive feedback on Androxal from FDA

Read More

Teva Pharma reports on rasagiline in early Parkinson's disease

Read More

Tranilast obtains orphan drug status for prevention of scarring in glaucoma surgery

Read More

Endo submits NDA for crush-resistant oxymorphone to FDA and plans to acquire Penwest

Read More

Amarin advances phase III AMR-101 trials in patients with high trigliceride levels

Read More

GSK and Genmab report topline data on ofatumumab in chronic lymphocytic leukemia

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 8, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • China compass

    ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

    BioWorld
    If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • Woman taking medication for mental illness

    Autobahn on the fast track with bipolar thyroid agonist

    BioWorld
    Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing